摘要
目的探讨前列腺癌组织中P504S蛋白表达变化及其与肿瘤细胞增殖侵袭活性的相关性。方法选取在本院确诊并接受治疗的前列腺癌患者79例作为前列腺癌组、同期在本院接受治疗的前列腺增生等前列腺良性病变患者90例作为前列腺良性病变组。对比两组病灶组织中P504S蛋白及前列腺癌增殖、侵袭相关蛋白表达量的差异。采用Pearson检验评估前列腺癌组织中P504S蛋白表达量与癌细胞增殖、侵袭活性的相关性。结果前列腺癌组P504S蛋白表达量显著高于前列腺良性病变组,增殖相关蛋白SLP-2、ADAM17、EZH2、Sp1的表达量显著高于前列腺良性病变组,侵袭相关蛋白DIAPH3、PEDF的表达量显著低于前列腺良性病变组,GPRC6A、Pttg1、MMP13的表达量显著高于前列腺良性病变组,差异均有统计学意义(P<0.05)。相关性分析发现,前列腺癌病灶中P504S蛋白表达量与癌细胞增殖、侵袭活性均呈正相关。结论前列腺癌组织中P504S蛋白表达量异常升高,可促进癌细胞增殖和侵袭。
Objective To study the expression of P504S protein in prostate cancer and its correlation with tumor cell proliferation and invasion activity.Methods Seventy-nine cases of prostate cancer patients who underwent treatment in our hospital during April 2015 and March 2018 were chosen as prostate cancer group.Ninety cases of prostatic hyperplasia patients in our hospital during the same period were chosen as benign prostatic lesion group.The expression of P504S protein and that of proteins related with proliferation and invasion in focal tissues were compared between the two groups.Pearson test was used to evaluate the correlation between P504S protein in prostate cancer and proliferation,invasion activity of cancer cells.Results Expression of P504S protein in prostate cancer group was significantly higher than that in benign prostatic lesion group(P<0.05).The expressions of proliferation-related proteins such as SLP-2,ADAM17,EZH2,Sp1 in prostate cancer group were higher than those in benign prostatic lesion group(P<0.05).The expressions of invasive-related proteins such as DIAPH3 and PEDF were lower in prostate cancer group than those in benign prostatic lesion group,while the expression of GPRC6A,Pttg1 and MMP13 were higher than those in benign prostatic lesion group(P<0.05).Correlation analysis showed that the expression of P504S protein in prostate cancer was positively correlated with proliferation and invasive activity of cancer cells.Conclusion Abnormal increasing of P504S protein expression in prostate cancer tissue can promote the proliferation and invasion in cancer cells.
作者
王凯
曲弘辰
谢庆鹏
孙浩
胡滨
WANG Kai;QU Hongchen;XIE Qingpeng;SUN Hao;HU Bin(Department of Urology,Liaoning Cancer Hospital,Shenyang,Liaoning,110044,China)
出处
《肿瘤药学》
CAS
2019年第1期90-93,共4页
Anti-Tumor Pharmacy
基金
辽宁省科技厅项目(2012225018)
关键词
前列腺癌
P504S
增殖
侵袭
Prostatic cancer
P504S
Proliferation
Invasiveness